<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01930292</url>
  </required_header>
  <id_info>
    <org_study_id>Debio 1143-103</org_study_id>
    <secondary_id>2012-003676-40</secondary_id>
    <nct_id>NCT01930292</nct_id>
  </id_info>
  <brief_title>Debio 1143 in Combination With Carboplatin and Paclitaxel in Patient With Advanced Solid Malignancies</brief_title>
  <official_title>A Phase I Study to Evaluate the Safety and Determine the Maximum Tolerated Dose (MTD) of Debio 1143 Combined With Carboplatin and Paclitaxel in Patients With Squamous Non-Small Cell Lung Cancer (NSCLC), Platinum-refractory Ovarian Cancer, and Basal-like/Claudin Low Triple Negative Breast Cancer (TNBC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Debiopharm International SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Debiopharm International SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a two-part trial in patients with squamous non-small cell lung cancer (NSCLC),
      platinum (Pt)-refractory ovarian cancer, and basal-like/claudin low triple negative breast
      cancer (TNBC).

      The primary objective of Part A is to determine the maximum tolerated dose (MTD) of Debio
      1143 when administered to these patients in combination with full doses of paclitaxel and
      carboplatin.

      The primary objective of Part B is to consolidate the safety profile of the recommended dose
      of Debio 1143 when administered to these patients in combination with full doses of
      paclitaxel and carboplatin.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Part B was cancelled based on business decision
  </why_stopped>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Number of participants with dose-limiting toxicities</measure>
    <time_frame>up to 18 weeks</time_frame>
    <description>Categories: each Debio 1143 dose level and overall</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Percentage of participants with adverse events (AEs) and serious AEs (SAEs) according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) criteria</measure>
    <time_frame>up to 18 weeks + 28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A: Percentage of participants with AEs and serious adverse events (SAEs) according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) criteria</measure>
    <time_frame>up to 18 weeks + 28 days</time_frame>
    <description>Categories: each Debio 1143 dose level and overall</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Number of participants with change in vital signs</measure>
    <time_frame>up to 18 weeks</time_frame>
    <description>Categories: each Debio 1143 dose level and overall</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Number of participants with change in electrocardiogram (ECG)</measure>
    <time_frame>up to 18 weeks</time_frame>
    <description>Categories: each Debio 1143 dose level and overall</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Number of participants with change in Eastern Cooperative Oncology Group (ECOG) performance status (PS)</measure>
    <time_frame>up to 18 weeks</time_frame>
    <description>Categories: each Debio 1143 dose level and overall</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Number of participants with change in vital signs</measure>
    <time_frame>up to 18 weeks</time_frame>
    <description>Categories: each indication at the recommended dose (RD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Number of participants with change in electrocardiogram (ECG)</measure>
    <time_frame>up to 18 weeks</time_frame>
    <description>Categories: each indication at the recommended dose (RD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Number of participants with change in Eastern Cooperative Oncology Group (ECOG) performance status (PS)</measure>
    <time_frame>up to 18 weeks</time_frame>
    <description>Categories: each indication at the recommended dose (RD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Percentage of participants with incidence of laboratory abnormalities according to NCI-CTCAE criteria</measure>
    <time_frame>up to 18 weeks</time_frame>
    <description>Categories: each Debio 1143 dose level and overall</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Percentage of participants with incidence of laboratory abnormalities according to NCI-CTCAE criteria</measure>
    <time_frame>up to 18 weeks</time_frame>
    <description>Categories: each indication at the RD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Percentage of participants with treatment discontinuations due to AEs and SAEs</measure>
    <time_frame>up to 18 weeks + 28 days</time_frame>
    <description>Categories: each Debio 1143 dose level and overall</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Percentage of participants with treatment discontinuations due to AEs and SAEs</measure>
    <time_frame>up to 18 weeks + 28 days</time_frame>
    <description>Categories: each indication at the RD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Number of participants with change in left ventricular ejection fraction (LVEF)</measure>
    <time_frame>up to 18 weeks</time_frame>
    <description>Categories: each Debio 1143 dose level and overall</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Number of participants with change in left ventricular ejection fraction (LVEF)</measure>
    <time_frame>up to 18 weeks</time_frame>
    <description>Categories: each indication at the RD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Number of participants with tumour response: disease control, change in tumour size from baseline and overall response</measure>
    <time_frame>up to 18 weeks</time_frame>
    <description>Categories: each Debio 1143 dose level and overall</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Number of participants with tumour response: disease control, change in tumour size from baseline and overall response</measure>
    <time_frame>up to 18 weeks</time_frame>
    <description>Categories: each indication at the RD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Percentage of participants with progression-free survival (PFS) at 6 months</measure>
    <time_frame>at 6 months</time_frame>
    <description>Categories: each Debio 1143 dose level and overall</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Percentage of participants with progression-free survival (PFS) at 6 months</measure>
    <time_frame>at 6 months</time_frame>
    <description>Categories: each indication at the RD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Percentage of participants with survival at 1 year</measure>
    <time_frame>at 12 months</time_frame>
    <description>Categories: each Debio 1143 dose level and overall</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Percentage of participants with survival at 1 year</measure>
    <time_frame>at 12 months</time_frame>
    <description>Categories: each indication at the RD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Maximum concentration (Cmax) in the pharmacokinetic (PK) subset</measure>
    <time_frame>up to 18 weeks</time_frame>
    <description>Categories: Debio 1143 alone; Debio 1143 when administered with paclitaxel and carboplatin; paclitaxel, 6αOH-paclitaxel (metabolite), and carboplatin (total and free Pt) when administered as chemotherapy alone; paclitaxel, 6αOH-paclitaxel (metabolite), and carboplatin (total and free Pt) when administered in combination with Debio 1143</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Lowest concentration before the next dose (Ctrough) of Debio 1143 in the PK subset</measure>
    <time_frame>up to 18 weeks</time_frame>
    <description>Categories: alone and in combination with chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Time to maximum concentration (tmax) in the PK subset</measure>
    <time_frame>up to 18 weeks</time_frame>
    <description>Categories: Debio 1143 alone; Debio 1143 when administered with paclitaxel and carboplatin; paclitaxel, 6αOH-paclitaxel (metabolite), and carboplatin (total and free Pt) when administered as chemotherapy alone; paclitaxel, 6αOH-paclitaxel (metabolite), and carboplatin (total and free Pt) when administered in combination with Debio 1143</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Area under the concentration versus time curve from the beginning to a point in time (AUC0-t) in the PK subset</measure>
    <time_frame>up to 18 weeks</time_frame>
    <description>Categories: Debio 1143 alone; Debio 1143 when administered with paclitaxel and carboplatin; paclitaxel, 6αOH-paclitaxel (metabolite), and carboplatin (total and free Pt) when administered as chemotherapy alone; paclitaxel, 6αOH-paclitaxel (metabolite), and carboplatin (total and free Pt) when administered in combination with Debio 1143</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Area under the concentration versus time curve extrapolated to infinity (AUC∞) in the PK subset</measure>
    <time_frame>up to 18 weeks</time_frame>
    <description>Categories: Debio 1143 alone; Debio 1143 when administered with paclitaxel and carboplatin; paclitaxel, 6αOH-paclitaxel (metabolite), and carboplatin (total and free Pt) when administered as chemotherapy alone; paclitaxel, 6αOH-paclitaxel (metabolite), and carboplatin (total and free Pt) when administered in combination with Debio 1143</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Terminal rate constant (λz) in the PK subset</measure>
    <time_frame>up to 18 weeks</time_frame>
    <description>Categories: Debio 1143 alone; Debio 1143 when administered with paclitaxel and carboplatin; paclitaxel, 6αOH-paclitaxel (metabolite), and carboplatin (total and free Pt) when administered as chemotherapy alone; paclitaxel, 6αOH-paclitaxel (metabolite), and carboplatin (total and free Pt) when administered in combination with Debio 1143</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Apparent terminal half-life (t½) in the PK subset</measure>
    <time_frame>up to 18 weeks</time_frame>
    <description>Categories: Debio 1143 alone; Debio 1143 when administered with paclitaxel and carboplatin; paclitaxel, 6αOH-paclitaxel (metabolite), and carboplatin (total and free Pt) when administered as chemotherapy alone; paclitaxel, 6αOH-paclitaxel (metabolite), and carboplatin (total and free Pt) when administered in combination with Debio 1143</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Mean residence time (MRT) in the PK subset</measure>
    <time_frame>up to 18 weeks</time_frame>
    <description>Categories: Debio 1143 alone; Debio 1143 when administered with paclitaxel and carboplatin; paclitaxel, 6αOH-paclitaxel (metabolite), and carboplatin (total and free Pt) when administered as chemotherapy alone; paclitaxel, 6αOH-paclitaxel (metabolite), and carboplatin (total and free Pt) when administered in combination with Debio 1143</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Apparent clearance (CL/F) of Debio 1143 in the PK subset</measure>
    <time_frame>up to 18 weeks</time_frame>
    <description>Categories: alone and in combination with chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Apparent volume of distribution during the terminal phase (Vz/F) of Debio 1143 in the PK subset</measure>
    <time_frame>up to 18 weeks</time_frame>
    <description>Categories: alone and in combination with chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Total amount of Debio 1143 excreted in urine (Ae) in the PK subset</measure>
    <time_frame>up to 18 weeks</time_frame>
    <description>Categories: alone and in combination with chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Total amount of Debio 1143 excreted in urine in the first 8 hours (Ae0-8) in the PK subset</measure>
    <time_frame>up to 18 weeks</time_frame>
    <description>Categories: alone and in combination with chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Total amount of Debio 1143 excreted in urine between 8 and 24 hours (Ae8-24) in the PK subset</measure>
    <time_frame>up to 18 weeks</time_frame>
    <description>Categories: alone and in combination with chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Renal clearance calculated as Ae/AUC∞ (CLR) of Debio 1143 in the PK subset</measure>
    <time_frame>up to 18 weeks</time_frame>
    <description>Categories: alone and in combination with chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Fraction of the dose excreted in urine calculated as Ae/dose (fe) of Debio 1143 in the PK subset</measure>
    <time_frame>up to 18 weeks</time_frame>
    <description>Categories: alone and in combination with chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Area under the concentration versus time curve in the first 12 hours (AUC0-12) in the PK subset</measure>
    <time_frame>up to 18 weeks</time_frame>
    <description>Categories: paclitaxel, 6αOH-paclitaxel (metabolite), and carboplatin (total and free Pt) when administered as chemotherapy alone; paclitaxel, 6αOH-paclitaxel (metabolite), and carboplatin (total and free Pt) when administered in combination with Debio 1143</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Total body clearance (CL) in the PK subset</measure>
    <time_frame>up to 18 weeks</time_frame>
    <description>Categories: paclitaxel, 6αOH-paclitaxel (metabolite), and carboplatin (total and free Pt) when administered as chemotherapy alone; paclitaxel, 6αOH-paclitaxel (metabolite), and carboplatin (total and free Pt) when administered in combination with Debio 1143</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Volume of distribution at steady-state (Vss) in the PK subset</measure>
    <time_frame>up to 18 weeks</time_frame>
    <description>Categories: paclitaxel, 6αOH-paclitaxel (metabolite), and carboplatin (total and free Pt) when administered as chemotherapy alone; paclitaxel, 6αOH-paclitaxel (metabolite), and carboplatin (total and free Pt) when administered in combination with Debio 1143</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Mean Residence Area under the concentration versus time curve (MR,AUC) in the PK subset</measure>
    <time_frame>up to 18 weeks</time_frame>
    <description>Categories: paclitaxel, 6αOH-paclitaxel (metabolite), and carboplatin (total and free Pt) when administered as chemotherapy alone; paclitaxel, 6αOH-paclitaxel (metabolite), and carboplatin (total and free Pt) when administered in combination with Debio 1143</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Mean Residence Maximum Concentration (MR,Cmax) in the PK subset</measure>
    <time_frame>up to 18 weeks</time_frame>
    <description>Categories: paclitaxel, 6αOH-paclitaxel (metabolite), and carboplatin (total and free Pt) when administered as chemotherapy alone; paclitaxel, 6αOH-paclitaxel (metabolite), and carboplatin (total and free Pt) when administered in combination with Debio 1143</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Platinum Refraction (PtR) in ovarian cancer participants included in the PK subset</measure>
    <time_frame>up to 18 weeks</time_frame>
    <description>Categories: paclitaxel, 6αOH-paclitaxel (metabolite), and carboplatin (total and free Pt) when administered as chemotherapy alone; paclitaxel, 6αOH-paclitaxel (metabolite), and carboplatin (total and free Pt) when administered in combination with Debio 1143</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Cmax in patients other than the PK subset</measure>
    <time_frame>up to 18 weeks</time_frame>
    <description>Categories: paclitaxel, 6αOH-paclitaxel (metabolite), and carboplatin (total and free Pt) when administered as chemotherapy alone; paclitaxel, 6αOH-paclitaxel (metabolite), and carboplatin (total and free Pt) when administered in combination with Debio 1143</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Concentration observed at time n (Cn) following Debio 1143 administration in patients other than the PK subset</measure>
    <time_frame>up to 18 weeks</time_frame>
    <description>Categories: paclitaxel, 6αOH-paclitaxel (metabolite), and carboplatin (total and free Pt) when administered as chemotherapy alone; paclitaxel, 6αOH-paclitaxel (metabolite), and carboplatin (total and free Pt) when administered in combination with Debio 1143</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Part A: Debio 1143</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible participants receive Part A: Debio 1143 once daily for 5 consecutive days in each 21-day treatment cycle according to dose escalation rules (in combination with Paclitaxel and Carboplatin standard of care)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Lung Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with Lung Cancer receive Part B: Debio 1143 once daily for 5 consecutive days in each 21-day treatment cycle (in combination with Paclitaxel and Carboplatin standard of care)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Ovarian Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with Ovarian Cancer receive Part B: Debio 1143 once daily for 5 consecutive days in each 21-day treatment cycle (in combination with Paclitaxel and Carboplatin standard of care)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Breast Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with Breast Cancer receive Part B: Debio 1143 once daily for 5 consecutive days in each 21-day treatment cycle (in combination with Paclitaxel and Carboplatin standard of care)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part A: Debio 1143</intervention_name>
    <description>Adaptive doses of Debio1143 oral capsules, between 50 and 400 mg until the recommended dose (RD) is determined.</description>
    <arm_group_label>Part A: Debio 1143</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel standard of care, intravenous (IV), once on day 1 or 2 of each 21-day treatment cycle, after pre-medication to prevent severe hypersensitivity reactions.</description>
    <arm_group_label>Part A: Debio 1143</arm_group_label>
    <arm_group_label>Part B: Lung Cancer</arm_group_label>
    <arm_group_label>Part B: Ovarian Cancer</arm_group_label>
    <arm_group_label>Part B: Breast Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin standard of care, intravenous (IV), once on day 1 or 2 of each 21-day treatment cycle.</description>
    <arm_group_label>Part A: Debio 1143</arm_group_label>
    <arm_group_label>Part B: Lung Cancer</arm_group_label>
    <arm_group_label>Part B: Ovarian Cancer</arm_group_label>
    <arm_group_label>Part B: Breast Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part B: Debio 1143</intervention_name>
    <description>RD of Debio1143 oral capsules, once daily for five consecutive days starting on day 1 or 2 of each 21-day treatment cycle.</description>
    <arm_group_label>Part B: Lung Cancer</arm_group_label>
    <arm_group_label>Part B: Ovarian Cancer</arm_group_label>
    <arm_group_label>Part B: Breast Cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets protocol-specified criteria for qualification and contraception

          -  Is willing and able to remain confined in the study unit for the entire duration of
             each treatment period and comply with restrictions related to food, drink and
             medications

          -  Voluntarily consents to participate and provides written informed consent prior to any
             protocol-specific procedures

        Exclusion Criteria:

          -  Has history or current use of over-the-counter medications, dietary supplements, or
             drugs (including nicotine and alcohol) outside protocol-specified parameters

          -  Has signs, symptoms or history of any condition that, per protocol or in the opinion
             of the investigator, might compromise:

               1. the safety or well-being of the participant or study staff;

               2. the safety or well-being of the participant's offspring (such as through
                  pregnancy or breast-feeding); or

               3. the analysis of results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Pierre Delord, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Claudius Regaud, Toulouse, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.debiopharm.com</url>
    <description>Site Debiopharm SA</description>
  </link>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2013</study_first_submitted>
  <study_first_submitted_qc>August 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2013</study_first_posted>
  <last_update_submitted>March 23, 2016</last_update_submitted>
  <last_update_submitted_qc>March 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

